Associated Genetic Biomarkers
NF1 Deletion is present in 0.07% of AACR GENIE cases.
NF1 Deletion serves as an inclusion eligibility criterion in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain NF1 Deletion as an inclusion criterion, 2 are phase 2 (2 open).
Trials with NF1 Deletion in the inclusion eligibility criteria most commonly target malignant solid tumor, B-cell non-hodgkin lymphoma, and multiple myeloma .
Temsirolimus and trametinib are the most frequent therapies in trials with NF1 Deletion as an inclusion criteria .
Significance of NF1 Deletion in Diseases
Malignant Solid Tumor +
NF1 is mutated in 5.52% of malignant solid tumor patients with NF1 Deletion present in 0.07% of all malignant solid tumor patients .
NF1 Deletion is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain NF1 Deletion and malignant solid tumor as inclusion criteria, 2 are phase 2 (2 open) .
B-Cell Non-Hodgkin Lymphoma +
NF1 is mutated in 1.93% of B-cell non-hodgkin lymphoma patients .
NF1 Deletion is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Deletion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) .
Multiple Myeloma +
NF1 Deletion is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains NF1 Deletion and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.